Author | Lauren C. Harshman, MD | OncLive

Author | Lauren C. Harshman, MD

Articles

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

December 04, 2019

Article

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Dr. Harshman on Earlier Use of Immunotherapy in RCC

May 18, 2018

Video

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).

Dr. Harshman Discusses the Potential for New RCC Treatments

May 10, 2018

Video

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.

Dr. Harshman on the PROTECT Trial in Patients With Locally Advanced RCC

April 06, 2018

Video

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses how the PROTECT trial sought to answer the controversial results of the ASSURE and S-TRAC trials.

x